Developing and commercializes diagnostic platforms.
Zyomyx has a unique expertise in and passion for tackling difficult “outside-the-box” problems. Highly user-friendly, instrument-free point-of-care tests need to be designed with an advanced level of cartridge engineering and reagent stability, and aligned with aggressive cost targets. Zyomyx specializes in exactly these demanding product requirements. Our immediate focus is an advanced, but simple to use and inexpensive CD4 T-cell point-of-care test that will be launched globally and configured to especially meet the demanding specifications for use in low and middle income countries.
Funding and Financing Rounds
Mar, 2014 / $7,5M / Seed / Other / Grant
Jul, 2013 / $14,22M / Seed / Other / Equity
Jun, 2013 / $12M / Series B / PRI / Equity
2011 / $6M / PRI
- Social Policies and Performance
Impact Reports & Metrics
6519 Dumbarton Circle
Fremont, California 94555
United States of America